Literature DB >> 10022467

Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2.

A B Lentsch1, F N Miller, M J Edwards.   

Abstract

In this review we discuss the effects of interleukin-2 (IL-2) therapy on trafficking of leukocytes and platelets to normal organs. The use of animal models has allowed the elucidation of events leading to damage and/or dysfunction of normal tissues after IL-2 administration. These studies have shown that acute toxicity induced by IL-2 is mediated primarily by neutrophils. Chronic toxicity results from the adhesion and transmigration of activated lymphocytes into normal organs. Platelet-derived microvascular thrombosis also contributes to the vascular toxicity of IL-2. A better understanding of these mechanisms may lead to the development of interventions that will significantly improve the therapeutic efficacy of IL-2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022467     DOI: 10.1007/s002620050527

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.

Authors:  L Pasqualini; M Pirro; R Lombardini; G Ciuffetti; P Dragani; E Mannarino
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.

Authors:  Lauryn E Klevorn; Melissa M Berrien-Elliott; Jinyun Yuan; Lindsey M Kuehm; Gregory D Felock; Sean A Crowe; Ryan M Teague
Journal:  Cancer Immunol Res       Date:  2016-11-01       Impact factor: 11.151

3.  Systemic administration of interleukin-2 inhibits inflammatory neutrophil migration: role of nitric oxide.

Authors:  Susana E Moreno; José C Alves-Filho; Giuliana Bertozi; Tais M Alfaya; Jacques Thèze; Sergio H Ferreira; Bernardo Boris Vargaftig
Journal:  Br J Pharmacol       Date:  2006-07-24       Impact factor: 8.739

4.  Comparison of vascular leak syndrome in mice treated with IL21 or IL2.

Authors:  Pallavur V Sivakumar; Richard Garcia; Kimberly S Waggie; Monica Anderson-Haley; Andrew Nelson; Steven D Hughes
Journal:  Comp Med       Date:  2013-02       Impact factor: 0.982

5.  Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma.

Authors:  Hongbing Guan; Narendra P Singh; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

6.  Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Gwang Hun Jeong; Keum Hwa Lee; I Re Lee; Ji Hyun Oh; Dong Wook Kim; Jae Won Shin; Andreas Kronbichler; Michael Eisenhut; Hans J van der Vliet; Omar Abdel-Rahman; Brendon Stubbs; Marco Solmi; Nicola Veronese; Elena Dragioti; Ai Koyanagi; Joaquim Radua; Jae Il Shin
Journal:  J Clin Med       Date:  2019-01-26       Impact factor: 4.241

Review 7.  The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation.

Authors:  Sabrina Copsel; Dietlinde Wolf; Krishna V Komanduri; Robert B Levy
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

Review 8.  Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy.

Authors:  Shee Kwan Phung; Jeffrey S Miller; Martin Felices
Journal:  Mol Diagn Ther       Date:  2021-07-29       Impact factor: 4.074

9.  Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma.

Authors:  Laura S Lourdes; Samer Z Al-Quran; Nam H Dang; Merry-Jennifer Markham
Journal:  Case Rep Hematol       Date:  2012-03-26

Review 10.  Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Authors:  Minh N Pham; Matthias G von Herrath; Jose Luis Vela
Journal:  Front Immunol       Date:  2016-01-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.